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Background: Autism is a pervasive neurodevelopmental disorder. At present there are no defined mechanisms of
pathogenesis and therapy is mostly limited to behavioral interventions. Stem cell transplantation may offer a
unique treatment strategy for autism due to immune and neural dysregulation observed in this disease. This
non-randomized, open-label, single center phase I/II trial investigated the safety and efficacy of combined
transplantation of human cord blood mononuclear cells (CBMNCs) and umbilical cord-derived mesenchymal stem
cells (UCMSCs) in treating children with autism.
Methods: 37 subjects diagnosed with autism were enrolled into this study and divided into three groups: CBMNC
group (14 subjects, received CBMNC transplantation and rehabilitation therapy), Combination group (9 subjects,
received both CBMNC and UCMSC transplantation and rehabilitation therapy), and Control group (14 subjects,
received only rehabilitation therapy). Transplantations included four stem cell infusions through intravenous and
intrathecal injections once a week. Treatment safety was evaluated with laboratory examinations and clinical
assessment of adverse effects. The Childhood Autism Rating Scale (CARS), Clinical Global Impression (CGI) scale and
Aberrant Behavior Checklist (ABC) were adopted to assess the therapeutic efficacy at baseline (pre-treatment) and
following treatment.
Results: There were no significant safety issues related to the treatment and no observed severe adverse effects.
Statistically significant differences were shown on CARS, ABC scores and CGI evaluation in the two treatment
groups compared to the control at 24 weeks post-treatment (p < 0.05).
Conclusions: Transplantation of CBMNCs demonstrated efficacy compared to the control group; however, the
combination of CBMNCs and UCMSCs showed larger therapeutic effects than the CBMNC transplantation alone.
There were no safety issues noted during infusion and the whole monitoring period.
Trial registration: ClinicalTrials.gov: NCT01343511, Title “Safety and Efficacy of Stem Cell Therapy in Patients with
Autism”.
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Autism spectrum disorders (ASD) are heterogeneous
neurodevelopmental disorders [1]. Autism is the most
prevalent ASD, characterized by dysfunctions in reciprocal
social interaction and communication, as well as presence
of repetitive and stereotypical behaviors [2]. Recent reports
have highlighted the dramatic rise in the number of chil-
dren affected with autism (57% growth compared with
2002) with current prevalence rate in the USA approaching
1% [3]. The exact etiology of autism remains unclear. Re-
search data have revealed that autism may result from a
complex combination of genetic and environmental factors
[2,4] and is associated with several biochemical events, in-
cluding ongoing cerebral hypoperfusion; immune dysre-
gulation and activation of neuroglial cells; decreased
methylation capacity; limited production of glutathione;
mitochondrial dysfunction; intestinal dysbiosis and oxida-
tive stress [5]. In addition, the triggering pathophysiology
and subsequent mechanisms of pathogenesis have not been
clarified. Consequently, identifying effective treatments for
autism is particularly difficult.
Current available therapeutic approaches for autism can
be broadly classified into behavioral, educational, medical,
allied health, and complementary and alternative medicine
interventions [6]. However, there is no defined standard
treatment intervention for children with autism [7,8]. Re-
cently, stem cell therapy showed great promise for the fu-
ture of regenerative medicines. Pre-clinical studies reported
that human cord blood mononuclear cell (CBMNC) trans-
plantation in animal models of brain ischemia could
promote functional recovery by improving local blood per-
fusion to damaged areas through angiogenesis [9,10]. In
addition, the CBMNC was safely transplanted for clinical
applications in non-hematopoietic degenerative conditions
in the absence of immune suppression [11,12]. Other data
revealed that mesenchymal stem cells (MSCs) represent re-
markable immunoregulatory properties by suppressing
proliferation and function of several major immune cells,
including T cells, B cells, natural killer (NK) cells, modulat-
ing the activities of dendritic cells (DC) and inducing regu-
latory T cells [13,14]. The authors hypothesized that the
combination of therapy modalities reveals robust preclin-
ical and human safety evidence to allow further study in
treating autism. This was a non-randomized, open-label,
controlled, single-center phase I/II clinical trial to examine
the treatment safety and efficacy of transplantation of
CBMNCs and/or human umbilical cord-derived mesen-
chymal stem cells (UCMSCs) in children with autism.
Methods
Study population and design
The study protocol and Informed Consent Forms were ap-
proved by the Institutional Review Board of the Shandong
Jiaotong Hospital under the auspices of the NationalMinistry of Health. Subjects were recruited from the
Shandong Jiaotong Hospital and Shandong Rehabilitation
Therapy Center between March and September 2009. Eli-
gible subjects included male or female (3 ~ 12 years of
age): diagnosed with autism, in accordance with the diag-
nostic criteria for autism in Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition (DSM-IV)
[15], and a score of Childhood Autism Rating Scale
(CARS) ≥ 30. Exclusion criteria included: 1) prior history
of severe allergic reactions; 2) any severe psychiatric dis-
order or an alternative ASD such as Asperger syndrome,
Rett syndrome or undefined pervasive developmental dis-
orders; 3) seizures within the past six months; 4) autism
caused by active epilepsy, cerebrovascular diseases or
brain trauma; 5) Severity of Illness (SI) of Clinical Global
Impression (CGI) scale evaluated as “Normal” or “Border-
line mentally ill” or “Mildly ill”; 6) moderate or severe
extrapyramidal symptoms or tardive dyskinesia; 7) severe
self-injury behavior; 8) active systemic or severe focal in-
fections, including human immunodeficiency virus (HIV),
syphilis and hepatitis; 9) autoimmune diseases; 10) severe
pulmonary and hematological diseases, malignancy or
hypoimmunity; 11) undertaking other treatments that may
affect the safety and efficacy evaluation of stem cell ther-
apy; 12) enrollment in other clinical trials in the last three
months; 13) other clinical conditions that the investigators
considered not appropriate for enrollment in this study.
After getting the signed Informed Consent Form from
individual subjects’ guardians, qualified investigators eval-
uated each subject’s condition based on the designed study
protocol. Enrolled subjects were divided into three groups:
the Control group, which received only rehabilitation
therapy; the CBMNC group, which received CBMNC
transplantation and rehabilitation therapy; and the Com-
bination group, which received combined CBMNC and
UCMSC transplantation and rehabilitation therapy. All
subjects received the same professional sensory integra-
tion and behavioral rehabilitation therapy at Shandong Re-
habilitation Therapy Center and had no other treatments
except those prescribed as part of the trial during the
study period. Each subject completed a 24-week follow-up
period by June 2010 (Figure 1).
Cell preparation and administration
The CBMNC and UCMSC were provided by Shenzhen
Beike Biotechnology Co., Ltd. Fresh human cord blood and
umbilical cord were obtained from informed healthy
donors in accordance with the sterile procurement guide-
lines established by the hospital in conjunction with the
National Ministry of Health. After collection, each sample
was tested for communicable diseases, including hepatitis
B, hepatitis C, HIV, cytomegalovirus and syphilis, as well
as the enzyme of alanine aminotransferase, and then
transferred for cell preparation in the GMP laboratories.
1 dropped out
37 children with autism were recruited and provided 
written informed consent
23 from Shandong Traffic Hospital
Divided into two experimental groups:
14 in CBMNC group (CBMNC 
transplantation and rehabilitation therapy);
9 in Combination group (CBMNC and 
UCMSC transplantation and rehabilitation 
therapy)
Baseline measurements performed in 23
23 underwent follow-up at 4w, 8w, 16w, 
24w and included in data analysis
14 from Shandong Mental Health Center
14 assigned to Control group 
(rehabilitation therapy)
13 underwent follow-up at 4w, 8w, 16w, 
24w and included in data analysis
Baseline measurements performed in 14
Figure 1 Enrollment and retention algorithm.
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30 mls of the diluted blood was then added to 15 mls of
Ficoll in every 50 ml centrifuge tube and then centrifuged
(750 g × 22 minutes). Mononuclear cells were collected
and washed twice in saline. Contaminating erythrocytes
were lyzed with lysis buffer comprising of injection grade
water. Cell density was adjusted to 2~6 × 106/ml and
seeded in Dulbecco’s modified Eagle’s medium: nutrient
mixture F-12 culture medium with basic fibroblast growth
factor and epidermal growth factor at a concentration of
20 ng/ml. Culture media was mixed with 2% v/v B-27
Stem Cell Culture Supplements. Cells were cultured at
37°C with saturated humidity and 5% CO2 by volume and
harvested for clinical application after 4 ~ 7 days of culti-
vation. The final CBMNC product contains 0.2 ~ 1.0%
CD34+ cells as determined by flow cytometry.
The umbilical cord was rinsed twice in normal saline
and the cord blood was removed during this process. The
washed cord was cut into 2-3 cm pieces and then bluntly
dissected to obtain Wharton’s jelly. The Wharton’s jelly
was cut into 1 ~ 4 mm3 pieces, floated in a flask with low-
glucose Dulbecco’s modified Eagle’s medium containing
serum substitute supplement, and subsequently incubated
at 37°C in a humidified atmosphere consisting of 5% CO2.
The medium was replaced every 3 ~ 5 days after the initial
plating. When well-developed colonies of fibroblast-like
cells appeared after 12 ~ 14 days, the cells were trypsinized
and passaged into a new flask for further expansion. The
UCMSCs harvested from passage 2 were used in this
study and flow cytometry results showed that ≥95% ofcells expressed CD29, CD73, CD90 and CD105, while the
expression of CD45, CD34, CD14, CD79 and HLA-DR
was 2% or less. The capacity of UCMSCs that differentiate
into adipogenic and osteogenic lineages was identified and
the soft agar cloning assay and tumorigenicity experiments
with UCMSCs in mice showed no carcinogenicity.
To ensure the quality of CBMNCs and UCMSCs, cell
growth was regularly monitored during the cultivation
and all the inspection information was recorded accord-
ingly, including test results for sterility, mycoplasma and
endotoxin (≤0.5 EU/ml). Any contaminated cell suspen-
sions or unhealthy cells were eliminated upon discovery.
The finished cell product incorporated a final cell count
as requested, cell viability (≥85%) determined by trypan
blue testing and sterility test.
After extensive discussion answering all questions, writ-
ten informed consents were obtained from each subject’s
guardian before initiating the scheduled treatments. With
the support from accumulated clinical experience of our
exploratory stem cell treatments [11,12,16], the subjects
recruited in the CBMNC and Combination groups received
four cell transplantations at an interval of 5 ~ 7 days. Ap-
proximately 2 × 106/kg CBMNCs and 1 × 106/kg UCMSCs
were infused with normal saline intravenously (20 ml) and/
or intrathecally (2 ml), respectively, per treatment. The
CBMNC group received the first transplantation through
intravenous infusion and subsequent three transplantations
through intrathecal injections. The Combination group re-
ceived two CBMNC intravenous and intrathecal infusions
each, followed by two UCMSC intrathecal injections.
Table 1 Baseline characteristics of enrolled patients
Variable CBMNC Combination Control
(N = 14) (N = 9) (N = 14)
Gender Male N(%) 13(92.86%) 9(100%) 14(100%)
Female N(%) 1(7.14%) 0(0.00%) 0(0.00%)
Age (year) Mean 7.41 ± 2.63 6.20 ± 2.12 5.60 ± 2.01
Median 7.08 6.51 5.02
Min-Max 3.29-12.02 3.98-9.83 3.51-10.02
Height(cm) Mean 102.86 ± 19.29 98.89 ± 23.56 86.21 ± 12.07
Median 105.00 90.00 82.50
Min-Max 80.00-130.00 75.00-130.00 70.00-120.00
Weight(Kg) Mean 28.32 ± 8.39 27.89 ± 7.85 21..5651 ± 7
Median 29.25 26.00 19.50
Min-Max 15.50-40.00 20.00-40.00 15.00-40.00
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Treatment safety was evaluated with: documentation of
physical examination, vital signs and adverse events;
complete blood count, liver and renal function, serum glu-
cose, lipid profile, immunology testing (including immuno-
globulin (Ig) A/G/M, complement C3/C4 and T-cell
subsets) at baseline (pre-treatment) and 4 (4w), 8 (8w), and
24 (24w) weeks after the first cell transplantation. Subjects
were assessed with CARS, CGI scale, and Aberrant Behav-
ior Checklist (ABC) at baseline and 4w, 8w, 16w and 24w
after the first cell transplantation for efficacy. All assess-
ments were conducted by physicians from the Shandong
Mental Health Center. The CARS and CGI evaluations
were the predetermined primary outcome measures and
the ABC was the secondary outcome measure.
CARS assesses behavior in 14 domains that are gener-
ally affected in autism, plus one general category for im-
pressions of features of autism, with the aim to identify
children with autism from other developmental disor-
ders [17]. The total score was classified as “no autism
(below 30)”, “mild or moderately autism (30 ~ 36.5)” or
“severe autism (above 36.5)”. The CGI assessment, a
widely used assessment tool in psychiatry for clinical tri-
als, is a 3-item observer-rated scale that measures illness
severity (SI), global improvement (GI) and therapeutic
effects (EI) [18]. The SI is rated on a 7-point scale, ran-
ging from 1 (normal) to 7 (most severely ill subjects)
and GI scores range from 1 (very much improved) to 7
(very much worse). EI ratings take account of both
therapeutic efficacy and treatment-related adverse events
and range from 0 (marked improvement with no side-
effects) and 4 (unchanged or worse with side-effects
outweighing the therapeutic effects). Five subscales are
designed in ABC to measure symptoms in children with
autism, including “Irritability”, “Lethargy/Social With-
drawal”, “Stereotypic Behavior”, “Hyperactivity” and “In-
appropriate Speech” and consisting of 58 items, each
rated on a 4-point scale [19,20].
Statistical analysis
Testing and evaluations were standardized and applied
equally across all subjects. Quantitative Data were
presented as means ± standard deviations (±s) and per-
centages were used to describe the qualitative data.
Independent-samples t-test and Wilcoxon signed-rank
test were used to compare the vital signs, including
blood pressure and heart rate, at each follow-up to base-
line measurements. Safety parameters were analyzed
with chi-square test or Fisher’s exact test at pre- and
post-treatment time points. To estimate the treatment
effect, differences in CARS and ABC scores in each
group were compared with multivariate analysis of vari-
ance (MANOVA) and in each time point using repeated
measures analysis of variance (ANOVA). Qualitative datafrom CGI scales were analyzed using K independent
samples rank sum test or two independent samples rank
sum test. Pearson’s correlation coefficient was applied to
correlate CARS and ABC scores. All statistical analyses
were performed using SPSS 13.0 statistical package
(SPSS, Chicago, IL, USA). A p-value <0.05 was consid-




A total of 37 participants with confirmed autism gave writ-
ten informed consent to participate in this trial (Figure 1).
Of these participants, 14 males from Shandong Rehabilita-
tion Therapy Center were enrolled in the Control group,
ranging in age from 3.51-10.02 (mean, 5.60 ± 2.01). One of
the 14 control subjects dropped out for reasons unrelated
to the trial and that dataset was not included in the safety
and efficacy analyses. The remaining 23 subjects from
Shandong Jiaotong Hospital were randomized to receive
stem cell therapy: 14 subjects in the CBMNC group, in-
cluding 13 males and 1 female, age ranging from 3.29-12.02
(mean, 7.41 ± 2.63), and 9 male subjects in the Combin-
ation group, ranging in age from 3.98-9.83 (mean, 6.20 ±
2.12). There were no statistically significant differences in
the demographic data, including age, height and weight,
among the three groups (P > 0.05, Table 1).
Safety measurement
All subjects had normal and stable vital signs during the
treatment course. Five subjects transiently developed low-
grade fever (3 subjects in the CBMNC group and 2 in the
Combination group) and recovered without medical inter-
ventions. No allergic, immunological reactions or other
serious adverse events were observed at the time of injec-
tion or during the whole follow-up period in the two
groups receiving stem cell transplantation. There were no
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renal laboratory changes post-treatment compared to
baseline (Table 2). Other safety measures, including
complete blood count, serum glucose, lipid profile and im-
munological parameters (Ig A/G/M, C3/C4 and T-cell
subsets), showed no significant changes from baseline.
Primary outcomes
Childhood autism rating scale
Behavioral therapy alone in the Control group was ef-
fective at reducing total scores in CARS after 24w
(Table 3). The total scores obtained following CARS as-
sessment were decreased from 45.11 ± 4.31 at baseline to
28.00 ± 6.18 at 24w in the Combination group, 46.43 ±
8.65 at baseline to 37.14 ± 10.15 at 24w in the CBMNC
group, and 43.15 ± 4.38 at baseline to 37.23 ± 3.42 at
24w in the Control group. Total CARS scores were sig-
nificantly decreased in the Combination group com-
pared with CBMNC and Control groups at 24w
(Table 3; p < 0.05). The changes in total CARS scores
represented a decrease of 37.9% in the Combination
group, which were significantly different to the changes
of 20.0% observed in the CBMNC group and 13.7% in
the Control groups (Table 3, p < 0.05). In addition, there
were significant differences for CARS scores in the
CBMNC group at 4w, 8w and 16w compared with base-
line (p < 0.05). The difference in CARS sub-scales were
compared among the groups at each designed time
point. Improvements in behaviors as determined for the
sub-scales of “Relating to people”, “Body use“, “Visual re-
sponse”, “Taste, smell, and touch response and use” and
“General impressions” in the Combination group were
observed when compared with the CBMNC and Control
groups (p < 0.05) (see Additional file 1: Table S1, “CARS
Scores”).
Clinical global impression scale
At baseline, no significant differences among the three
groups were observed in the CGI-SI scale (Table 4;
p > 0.05). For the Control group 50% were scored as “Mod-
erately ill”, 21% as “Markedly ill” and 21% as “Severely ill”
at baseline (Table 4). However, there were statistically sig-
nificant differences in CGI-SI in the Combination group
compared with the Control group at 24w (Table 4;Table 2 Serum biochemistry at pre- and post-treatment in th
Parameter ALT (U/L) AST (U/L)
Reference range 0 ~ 40 0 ~ 50
Baseline 27.71 ± 9.82 34.67 ± 8.49
4w 26.70 ± 9.42 35.00 ± 7.34
8w 26.45 ± 8.56 35.12 ± 6.38
24w 27.56 ± 8.46 35.76 ± 9.73
Note: ALT denotes alanine aminotransferase, AST aspartate aminotransferase, TBI toP < 0.05). At 24w, 92% of controls were considered “Mod-
erately ill”, whereas in the Combination group, the assess-
ments had improved with 11% considered “normal, not
ill”, 55% “Mildly ill” and only 33% classified as “Markedly
ill”. In comparison in the CBMNC group, 7% were consid-
ered “borderline”, 29% “Mildly ill”, 29% “Moderately ill”,
14% “Markedly ill” and 14% “Severely ill” at 24w. The fre-
quency of participants that were “Very much improved”
and “Much improved” based on the CGI-GI scale was in-
creased in the Combination group (88.89%) and CBMNC
group (50%) and was significantly different from the Con-
trol group (7.69%) at 24w (Table 5; p < 0.05). The fre-
quency of participants of “Marked” and “Moderate” effects
in the CGI-EI scale was also more pronounced in the
Combination group (88.89%), and CBMNC group (50%)
compared with the Control group (7.69%) at 24 W
(Table 5; p < 0.05).
Secondary outcomes
Aberrant behavior checklist
Compared with baseline assessments, there were signifi-
cant decreases in total ABC scores at 24w in the Combin-
ation (59.9%), CBMNC group (38.0%) and the Control
group (17.4%) (Table 6; p < 0.05). There were also signifi-
cant differences in total ABC scores at 8w and 16w in the
CBMNC group compared with baseline. At 24w post
treatment, there were significant differences of “Lethargy/
Social withdrawal”, “Stereotypic behavior” and total ABC
scores in the Combination group when compared with the
CBMNC and Control groups (p < 0.05). The scores were
no statistical differences of “Hyperactivity”, “Irritability” or
“Inappropriate speech” between the three groups at 24w
(p > 0.05). Interestingly, there was close correlation be-
tween the assessment results of ABC and CARS at each
evaluation point with strong associations between mean
total scores of ABC and CARS at each follow-up point
post treatment (see Additional file 1: Table S2, “Correl-
ation of ABC and CARS Scores”; p < 0.001).
Discussion
In the current proof-of-concept study we used CBMNC
and UCMSC transplantation in addition to conventional
behavioral therapies to test the potential effects of stem
cell therapies in children with autism. The preliminarye CBMNC and combination groups
TBI (μmol/L) BUN (μmol/L) SCR (μmol/L)
1.7 ~ 20.5 3.2 ~ 7.1 44 ~ 133
13.10 ± 7.20 5.67 ± 1.32 44.30 ± 8.20
12.78 ± 4.33 6.10 ± 1.24 42.56 ± 7.46
12.56 ± 4.21 6.21 ± 1.32 42.60 ± 7.66
13,45 ± 6.15 5.72 ± 1.56 43.57 ± 8.43
tal bilirubin, BUN blood urea nitrogen, and SCR Serum creatinine.
Table 3 CARS total score
Group Baseline 4w 8w 16w 24w
CBMNC 46.43 ± 8.65 *39.21 ± 8.63 *36.64 ± 7.07 *35.14 ± 7.77 37.14 ± 10.15
Combination 45.11 ± 4.31 40.67 ± 3.82 38.22 ± 9.74 36.78 ± 12.8 *28.00 ± 6.18ab
Control 43.15 ± 4.38 41.54 ± 3.82 41.46 ± 3.41 40.31 ± 3.82 *37.23 ± 3.42
Note: *Change in CARS scores at follow-up points compared to baseline in each group (p < 0.05). aThe CARS score of the Combination or CBMNC group at each evaluation
point compared with the Control group (p < 0.05). bThe CARS score of the Combination group at each evaluation point compared with the CBMNC group (p< 0.05).
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was safe and efficacious at the doses, formulation, method
of delivery and intervals treated. Compared with the
Control group, both objective functional and subjective
improvements were observed in visual, emotional and
intellectual responses, body use, adaption to change, fear
or nervousness, nonverbal communication and activity
level assessed by CARS, as well as in lethargy/social with-
drawal, stereotypic behavior, hyperactivity and inappropri-
ate speech evaluated by ABC in both the CBMNC and
Combination groups. Similarly, the CGI-SI, CGI-GI and
CGI-EL also showed statistical significant improvements
when compared with the Control group. Safety measure-
ments indicated that stem cell administration via intraven-
ous and intrathecal infusions were well tolerated without
immediate or long term side effects during the 24-week
follow-up period. The few cases with low-grade fever were
mild and resolved without special medical interventions.
With these results in this small cohort of subjects, the
risk-benefit ratio of stem cell therapy in autistic children
appears to be favorable.
While the pathophysiology of autism remains poorly de-
fined, accumulating data suggests that one potential eti-
ology may involve immune dysregulation (reviewed in
Onore et al. 2012) [21]. Extensive data indicate an abnor-
mal immune system, including active neuroinflammation
in the brain, elevated pro-inflammatory cytokine profiles,Table 4 CGI-SI scale at baseline and 24w
Scale Baseline
Combination CBMNC Contr
0 - n(%) 0(0.00%) 0(0.00%) 0(0.00
1 - n(%) 0(0.00%) 0(0.00%) 0(0.00
2 - n(%) 0(0.00%) 0(0.00%) 0(0.00
3 - n(%) 2(22.22%) 1(7.14%) 1(7.14
4 - n(%) 2(22.22%) 5(35.71%) 7(50.00
5 - n(%) 2(22.22%) 1(7.14%) 3(21.43
6 - n(%) 3(33.33%) 6(42.86%) 3(21.43
7 - n(%) 0(0.00%) 1(7.14%) 0(0.00
Total (missed) 9(0) 14(0) 14(0
Note: 0 = Not assessed; 1 = Normal, not at all ill; 2 = Borderline mentally ill; 3 = Mildl
extremely ill patients. *The frequency of participants who scored “Mildly ill” or bette
aThe frequency of participants who scored “Mildly ill” or better in the Combination
group at 24w (p < 0.05). bThe frequency of participants who scored “Mildly ill” or be
with the CBMNC group at 24w (p < 0.05).dysfunction of immune cells and presence of autoimmun-
ity, directly related to increased impairments in behavior.
Studies demonstrated an ongoing neuroinflammatory
process with marked activation of microglia and astroglia
in the cerebral cortex, white matter and cerebellum of in-
dividuals with autism [22]. A unique proinflammatory
cytokine profile in autistic patients has been documented
in the cerebrospinal fluid, including a marked increase in
macrophage chemoattractant protein-1 [22], and in the
peripheral plasma, such as significantly elevated levels of
interleukin (IL)-1β, IL-8 and IL-12p40 [23]. Additional
studies found altered function in immune cell subsets
[24-26], leading to an inappropriate or ineffective immune
response to pathogen challenge in autism. Various auto-
antibodies responding to the proteins in central nervous
system have been detected in the children with autism,
which might link autism with an autoimmune process ra-
ther than an externally triggered immune reaction [27-29].
Collectively, these data suggest that immune dysfunction
is not only a symptom/co-morbidity but indicative of an
underlying pathophysiological process, so that targeting
this pathology and modifying neuroimmune reactions
may be productive from the therapeutic perspective.
However, few clinical trials of anti-inflammatory drugs
have aimed to correct immune dysregulation/ongoing
neuroinflammation in autism. Due to their known abil-
ity to alter immune responses, MSCs may offer a novel24w
ol *Combinationab *CBMNCa Control
%) 0(0.00%) 0(0.00%) 1(7.69%)
%) 1(11.11%) 0(0.00%) 0(0.00%)
%) 0(0.00%) 1(7.14%) 0(0.00%)
%) 5(55.56%) 4(28.57%) 0(0.00%)
%) 3(33.33%) 4(28.57%) 12(92.31%)
%) 0(0.00%) 2(14.29%) 0(0.00%)
%) 0(0.00%) 2(14.29%) 1(7.69%)
%) 0(0.00%) 1(7.14%) 0(0.00%)
) 9(0) 14(0) 13(1)
y ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; 7 = Among the most
r was significantly increased at 24w when compared to baseline (p < 0.05).
or CBMNC group was significantly increased when compared with the Control
tter in the Combination group was significantly increased when compared
Table 5 CGI-GI and CGI-EI scales at 24w
CGI scale Combinationab CBMNCa Control
CGI-GI Not assessed 0(0.00%) 0(0.00%) 1(7.69%)
N (%) Very much improved 3(33.33%) 1(7.14%) 0(0.00%)
Much improved 5(55.56%) 6(42.86%) 1(7.69%)
Minimally improved 1(11.11%) 2(14.29%) 11(84.62%)
No change 0(0.00%) 5(35.71%) 1(7.69%)
Minimally worse 0(0.00%) 0(0.00%) 0(0.00%)
Much worse 0(0.00%) 0(0.00%) 0(0.00%)
Very much worse 0(0.00%) 0(0.00%) 0(0.00%)
CGI-EI Unchanged or worse 0(0.00%) 5(35.71%) 1(7.69%)
N (%) Minimal 1(11.11%) 2(14.29%) 11(84.62%)
Moderate 6(66.67%) 7(50.00%) 1(7.69%)
Marked 2(22.22%) 0(0.00%) 0(0.00%)
Total(missed) 9(0) 14(0) 13(1)
Note: aThe percent of “Very much improved” and “Much improved” in the CGI-
GI scale and the percent of “Marked” and “Moderate” effects in the CGI-EI
scale were significantly higher in the Combination and CBMNC groups when
compared with the Control group at 24w (p < 0.05). bThe percent of “Very
much improved” and “Much improved” in the CGI-GI scale and the percent of
“Marked” and “Moderate” effects in the CGI-EI scale were significantly higher
in the Combination group when compared with the CBMNC group at
24w (p < 0.05).
Lv et al. Journal of Translational Medicine 2013, 11:196 Page 7 of 10
http://www.translational-medicine.com/content/11/1/196therapeutic to ameliorate the immune abnormalities
apparent in some children with autism [13,14].
MSCs have profound immunoregulatory properties and
are currently being investigated as a novel cellular immuno-
modulatory and anti-inflammatory agent in numerous clin-
ical trials [30]. It has been shown that MSCs can reduce the
proliferative capacity of T cells, B cells, NK cells, DC and
neutrophils, and modulate a variety of immune cell func-
tions: cytokine secretion and cytotoxicity of T cells and NK
cells, B cell maturation and antibody secretion, DC matur-
ation and activation, as well as antigen presentation [13,31].
In addition, MSCs can secrete a plethora of growth factors,
anti-inflammatory cytokines and immunomodulatory medi-
ators, such as indoleamine 2,3-dioxygenase, prostaglandin
E2 (PGE2), nitric oxide, histocompatibility leucocyte
antigen-G, transforming growth factor-β, interferon-γ, hep-
atocyte growth factor (HGF), IL-6, IL-10 and heme
oxygenase-1 [14,32]. Recently, the mechanisms and mole-
cules involved in the immunoregulatory effect of UCMSCs
have been broadly revealed: suppressing the proliferation of
B cells by modifying the phosphorylation pattern of Akt
and p38 pathways [33]; mediating suppressive effects on T
cell proliferation through monocytes as an essential inter-
mediary [34]; and exerting immunomodulatory effects by
PGE2-mediated mechanism [35]. The administration of
UCMSCs to treat systemic lupus erythematosus has pro-
vided additional evidence for their immunoregulatory role
[16,36], supporting their use in controlling both auto-
immunity and triggered inflammation.Several studies have corroborated that cerebral hypoper-
fusion is associated with many core symptoms in autism
[37-41]. Generalized brain hypoperfusion, peaking in
frontal and prefrontal regions, was observed in children
with autism and associated with cognitive and neuro-
psychological defects [38]. In addition, decreased cerebral
perfusion, especially in the temporo-parietal areas, has
been related to cognitive impairment, such as language
deficits, impairment of cognitive development and object
representation, and abnormal perception and responses to
sensory stimuli [39]. Inadequate perfusion resulting in
brain tissue hypoxia not only caused neuronal apoptosis
and necrosis, but also led to abnormal brain tissue me-
tabolism and accumulation of pathological levels of
neurotransmitter [40]. Therapeutically targeting cerebral
ischemia and resulting hypoxia may be an alternative
therapeutic approach in autism [41]. Therapeutic angio-
genesis promoted by systemic administration of cord
blood CD34+ stem cells to overcome ischemia has been
experimentally demonstrated in vitro and animal models.
It has been proved that the endothelial progenitor cell,
contained in a CD34+ cell population enriched in
CBMNCs, has the capacity to trigger angiogenesis in the
ischemic tissues [42]. The circulating CD34+ progenitors
in CBMNCs with the potential for endothelial develop-
ment were recruited to the injury sites and developed into
new endothelial cells to either repair the injured endothe-
lial wall or sprout new vascular structure [43]. Moreover,
human CD34+ cells and hematopoietic precursors can se-
crete numerous angiogenic factors, such as vascular endo-
thelial growth factor (VEGF), HGF, and insulin-like
growth factor-1 [44]. These promising results with
CBMNC therapies have been successfully translated into
the pre-clinical application for functional recovery in vari-
ous ischemic animal models through the enhancement of
angiogenesis around the site of degeneration [9,45]. Given
the potency of cord blood CD34+ cells to promote angio-
genesis in ischemic areas, the CBMNC may be useful for
the improvement of the cerebral hypoperfusion and hyp-
oxia that has been suggested to occur in the brains of indi-
viduals with autism [37-41].
In this present study, we compared the therapeutic
efficacy of three groups: CBMNC transplantation with
rehabilitation therapy, combined transplantation of
CBMNCs and UCMSCs with rehabilitation therapy, and
rehabilitation therapy alone. The data demonstrated
that stem cell transplantation was more efficacious than
conventional rehabilitation therapy in improving some
features of autism. The mechanisms involved in improv-
ing the autistic symptoms might be through increased
perfusion in brain areas and/or the regulation of im-
mune dysfunction. Moreover, the Combination group
showed overall more robust therapeutic efficacy than the
CBMNC group, which may be attributed to the action of
Table 6 ABC score
ABC item Group Baseline 4w 8w 16w 24w
Irritability CBMNC 16.36 ± 9.61 14.00 ± 8.66 9.50 ± 8.81 10.21 ± 9.58 8.14 ± 8.37
Combination 15.00 ± 7.81 11.22 ± 5.76 9.78 ± 4.32 5.67 ± 3.24 4.22 ± 3.19
Control 9.15 ± 5.58 8.31 ± 5.41 8.46 ± 5.41 8.69 ± 5.56 6.92 ± 4.96
Lethargy/Social withdrawal CBMNC 30.71 ± 6.08 26.86 ± 5.26a 24.07 ± 7.08a 23.86 ± 8.62a 24.14 ± 9.65a
Combination 31.00 ± 6.98 25.78 ± 6.50a 22.67 ± 5.27a 21.11 ± 5.82a *16.00 ± 7.92ab
Control 35.08 ± 4.96 34.31 ± 5.14 33.92 ± 4.73 32.46 ± 5.55 *30.54 ± 5.03
Stereotypic behavior CBMNC 29.43 ± 9.77 *22.43 ± 8.98 *18.86 ± 10.52 *18.00 ± 10.86 *17.07 ± 9.93
Combination 28.33 ± 8.47 20.78 ± 8.81 17.22 ± 7.12 13.22 ± 6.78 *9.33 ± 5.81ab
Control 22.77 ± 6.86 20.85 ± 6.63 21.08 ± 4.82 18.38 ± 5.58 17.31 ± 4.05
Hyperactivity CBMNC 11.86 ± 4.55a 10.07 ± 4.63 7.57 ± 4.83 7.29 ± 5.27 6.86 ± 5.26
Combination 11.89 ± 6.88a 9.33 ± 5.87 7.22 ± 5.19 5.89 ± 3.37 4.67 ± 3.74
Control 6.08 ± 3.15 6.31 ± 2.81 6.46 ± 3.38 6.15 ± 3.39 5.08 ± 2.40
Inappropriate speech CBMNC 5.71 ± 4.30a 3.79 ± 3.29 3.43 ± 3.34 2.93 ± 2.87 2.14 ± 2.32
Combination 5.56 ± 2.83a 4.56 ± 2.92 3.11 ± 1.62 3.22 ± 2.44 2.56 ± 2.19
Control 2.38 ± 2.10 2.69 ± 2.21 3.00 ± 2.27 2.92 ± 2.56 2.46 ± 2.63
Total score CBMNC 94.07 ± 21.98 77.14 ± 22.4 *63.43 ± 29.93 *62.29 ± 33.98 *58.36 ± 31.73a
Combination 91.78 ± 25.92 71.67 ± 22.57 60.00 ± 18.94 49.11 ± 14.61 *36.78 ± 16.95ab
Control 75.46 ± 12.05 72.46 ± 12.95 72.92 ± 11.43 68.62 ± 12.58 *62.31 ± 11.3
Note: *Aberrant behavioral scores at different follow-up time-points compared with baseline scores in each group (p < 0.05). aAberrant behavioral scores of the
Combination or CBMNC group compared with the Control group (p < 0.05). bComparison of aberrant behavioral scores of the Combination group with the CBMNC
group (p < 0.05).
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therapeutic benefits. In addition to immunoregulation,
the cascade of cytokine spectrum triggered by UCMSCs
is supportive of hematopoiesis: promoting the homing
and expansion of transplanted CD34+ hematopoietic
stem/progenitor cells to boost engraftment, such as
stromal-derived factor-1; associating with hemato-
poietic stem cell proliferation, for example stem cell fac-
tor, macrophage colony-stimulating factor, granulocyte
macrophage colony-stimulating factor and granulocyte
colony-stimulating factor; and enhancing angiogenesis and
tissue repair by VEGF [46]. Transplanted MSCs might in-
tegrate into the altered brain and restore damaged func-
tions, promote synaptic plasticity and functional recovery,
and rescue cerebellar Purkinjie cells in autistic subjects
[47]. However, the exact mechanisms of CBMNC and
UCMSC transplantation to treat autism still remain un-
confirmed and need to be further clarified.
CARS, CGI and ABC scales were adopted to assess
the therapeutic efficacy in this study. CARS can provide
descriptive information about the pathological behavior
and classify the degree of severity in autistic children,
while the CGI scale, as a global measure, indicates the
noticeable overall effect of treatment. However, further
follow up studies will need to expand the behavioral
assessments to include the more standardized measures
in the Autism Diagnostic Observation Schedule. Studieshave demonstrated that ABC is suitable for clinical
quantitative evaluation of specific symptoms in children
with autism [19,48]. Recently, the reliability and validity
of the ABC Chinese Version (accurately translated from
the original English version) for the measurement of
therapeutic efficacy in Chinese children with autism
have been examined, which showed a high positive
correlation (r = 0.27 ~ 0.67, p < 0.01) with the CARS,
Autism Behavior Checklist, Conner Parent Symptom
Questionnaire and Achenbach Child Behavior Check list
[49]. A close correlation between the ABC and CARS
assessment results was consistently found in this study
at each evaluation point increasing sequentially from
baseline to 24w, also suggesting that the ABC is a useful
measure for the evaluation of therapeutic efficacy in
Chinese children with autism.
There are several limitations to this proof-of-concept
study. First, the subjects were not randomized and they
were not prospectively stratified based on disease severity
or other demographic variable. Fortunately, there was no
significant difference in the enrolled participants’ diagnos-
tic, cognitive, or physical health among three groups,
which allows for a valid comparison between groups.
Second, the number of the subjects enrolled in this study
was comparatively small, which may introduce bias in the
safety and efficacy measures. Third, the subjects were
followed for only 24 weeks and the long-term safety and
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nor evaluators were blinded, again possibly introducing
bias into the measurements. Finally, the exact action
mechanism was not known or clarified in this study.
Conclusion
In summary, CBMNC and UCMSC transplantation may
improve some behavioral symptoms and function ob-
served in children with autism. This study presents for
the first time a safety and efficacy analysis of using allo-
geneic CBMNCs and UCMSCs to treat behaviors in
addition to conventional behavioral therapy in autism.
With the safety profile of stem cell transplantation and
the efficacy documented in this proof-of-concept study,
large-scale randomized controlled double-blind studies
are warranted to better define this novel therapeutic
intervention on the long-term safety and efficacy in
treating autism.
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